Home
|
Help
|
Contact
Sign in
WPRIM Management System>
DCMS
>
Journal of Gynecologic Oncology
>
2022
>
33
>
6
Volume:
33
Issue:
6
1. Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective
Page:e86—
2. ASGO 7th International Workshop on Gynecologic Oncology
Page:e85—
3. LncRNA XIST promotes carboplatin resistance of ovarian cancer through activating autophagy via targeting miR-506-3p/FOXP1 axis
Page:e81—
4. Incidence of gastrointestinal perforation associated with bevacizumab in combination with neoadjuvant chemotherapy as first-line treatment of advanced ovarian, fallopian tube, or peritoneal cancer: analysis of a Japanese healthcare claims database
Page:e78—
5. High expression of folate receptor alpha is associated with poor prognosis in patients with cervical cancer
Page:e82—
6. Prognostic influence of an early time to chemotherapy following primary cytoreductive surgery for advanced epithelial ovarian cancer
Page:e80—
7. SP1-induced lncRNA MCF2L-AS1 promotes cisplatin resistance in ovarian cancer by regulating IGF2BP1/IGF2/MEK/ERK axis
Page:e75—
8. Prognostication of early-onset endometrioid endometrial cancer based on genome-wide DNA methylation profiles
Page:e74—
9. Immunonutrition in ovarian cancer: clinical and immunological impact?
Page:e77—
10. Epidemiologic study on gestational trophoblastic diseases in Japan
Page:e72—
11. Predicting prognosis according to the updated WHO classification in patients with endocervical adenocarcinoma treated with surgery and radiotherapy
Page:e71—
12. The impact of interval between primary cytoreductive surgery with bowel resection and initiation of adjuvant chemotherapy on survival of women with advanced ovarian cancer: a multicenter cohort study
Page:e76—
13. Randomized comparison between sentinel lymph node mapping using indocyanine green plus a fluorescent camera versus lymph node dissection in clinical stage I-II endometrial cancer: a Korean Gynecologic Oncology Group trial (KGOG2029/SELYE)
Page:e73—